These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 21273181

  • 1. Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy.
    Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Sakamori Y, Mio T, Mishima M.
    Clin Lung Cancer; 2011 Jan; 12(1):56-61. PubMed ID: 21273181
    [Abstract] [Full Text] [Related]

  • 2. Clinicopathological factors affecting progression-free survival of patients with previously treated advanced non-small cell lung cancer after S-1 therapy with or without bevacizumab.
    Masago K, Fujita S, Hata A, Kaji R, Ohtsuka K, Okuda C, Takeshita J, Katakami N.
    Anticancer Res; 2014 Dec; 34(12):7467-72. PubMed ID: 25503189
    [Abstract] [Full Text] [Related]

  • 3. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.
    Wu JY, Yu CJ, Shih JY, Yang CH, Yang PC.
    Lung Cancer; 2010 Mar; 67(3):348-54. PubMed ID: 19473721
    [Abstract] [Full Text] [Related]

  • 4. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp.
    Sutani A, Nagai Y, Udagawa K, Uchida Y, Koyama N, Murayama Y, Tanaka T, Miyazawa H, Nagata M, Kanazawa M, Hagiwara K, Kobayashi K.
    Br J Cancer; 2006 Dec 04; 95(11):1483-9. PubMed ID: 17106442
    [Abstract] [Full Text] [Related]

  • 5. Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib.
    Fujiwara Y, Kiura K, Toyooka S, Hotta K, Tabata M, Takigawa N, Soh J, Tanimoto Y, Kanehiro A, Kato K, Date H, Tanimoto M.
    Lung Cancer; 2008 Jan 04; 59(1):81-7. PubMed ID: 17765355
    [Abstract] [Full Text] [Related]

  • 6. Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib.
    Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Sakamori Y, Okuda C, Mio T, Mishima M.
    Oncology; 2010 Jan 04; 79(5-6):355-62. PubMed ID: 21430404
    [Abstract] [Full Text] [Related]

  • 7. Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment.
    Song ZB, Yu YF, Chen ZW, Lu S.
    Chin Med J (Engl); 2011 Aug 04; 124(15):2279-83. PubMed ID: 21933557
    [Abstract] [Full Text] [Related]

  • 8. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M.
    Lung Cancer; 2006 Jan 04; 51(1):89-96. PubMed ID: 16290256
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
    Zhang L, Yuan X, Chen Y, Du XJ, Yu S, Yang M.
    Gene; 2013 Mar 15; 517(1):60-4. PubMed ID: 23313300
    [Abstract] [Full Text] [Related]

  • 11. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
    Asami K, Koizumi T, Hirai K, Ameshima S, Tsukadaira A, Morozumi N, Morikawa A, Atagi S, Kawahara M.
    Clin Lung Cancer; 2011 Nov 15; 12(6):387-92. PubMed ID: 21729650
    [Abstract] [Full Text] [Related]

  • 12. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.
    J Clin Oncol; 2008 May 20; 26(15):2442-9. PubMed ID: 18458038
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
    Okuma Y, Hosomi Y, Nagamata M, Yamada Y, Sekihara K, Kato K, Hishima T, Okamura T.
    Anticancer Res; 2013 Nov 20; 33(11):5057-64. PubMed ID: 24222150
    [Abstract] [Full Text] [Related]

  • 15. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
    Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T, Yoshida K, Hirashima T, Yasumoto K, Sugio K, Mitsudomi T, Fukuoka M, Nukiwa T.
    Clin Cancer Res; 2009 Jul 01; 15(13):4493-8. PubMed ID: 19531624
    [Abstract] [Full Text] [Related]

  • 16. Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
    Dongiovanni D, Daniele L, Barone C, Dongiovanni V, Fissore C, Sapino A, Macrì L, Bussolati G, Buffoni L, Gaspari F, Grillo R, Birocco N, Addeo A, Ciuffreda L, Schena M.
    Lung Cancer; 2008 Jul 01; 61(1):73-81. PubMed ID: 18243402
    [Abstract] [Full Text] [Related]

  • 17. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
    Choi MK, Hong JY, Chang WJ, Kim MJ, Kim SM, Jung HA, Do IG, Choi YL, Sun JM, Ahn JS, Park K, Ahn MJ.
    Cancer Chemother Pharmacol; 2015 Jun 01; 75(6):1229-36. PubMed ID: 25903122
    [Abstract] [Full Text] [Related]

  • 18. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
    Goto K, Nishio M, Yamamoto N, Chikamori K, Hida T, Maemondo M, Katakami N, Kozuki T, Yoshioka H, Seto T, Fukuyama T, Tamura T.
    Lung Cancer; 2013 Oct 01; 82(1):109-14. PubMed ID: 23910906
    [Abstract] [Full Text] [Related]

  • 19. Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
    Song Z, Zhang Y.
    J Clin Neurosci; 2014 Apr 01; 21(4):591-5. PubMed ID: 24256883
    [Abstract] [Full Text] [Related]

  • 20. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
    Wu JY, Yu CJ, Yang CH, Wu SG, Chiu YH, Gow CH, Chang YC, Hsu YC, Wei PF, Shih JY, Yang PC.
    Am J Respir Crit Care Med; 2008 Oct 15; 178(8):847-53. PubMed ID: 18583573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.